The theory behind antibody drug conjugates (ADCs) is simple yet elegant: by combining the specificity of a monoclonal antibody with the cytotoxicity of a potent small molecule drug, ADCs can ...

Antibody drug conjugates have emerged as a potential option to selectively eliminate the tumor population, with minimal side ...

Highlighted by Genentech's recent US regulatory submission for trastuzumab–DM1, antibody–drug conjugation technology could be heading for the mainstream in anticancer drug development.

Sotio Biotech AS is exercising an option under a license and option agreement to obtain a license to Synaffix BV’s technology to develop two bispecific antibody-drug conjugate (ADC) programs for solid ...

Antibody-drug conjugates have had a tremendous impact on breast cancer care and treatment, according to Dr. Charles E. Geyer.

The scores also enable researchers to assess the spatial relationships critical to the mechanisms of antibody–drug conjugates (ADCs), such as the bystander effect, where a drug impacts not only the ...

A TROP2-directed antibody-drug conjugate, DB-1305/BNT325, demonstrated durable activity in patients with previously treated ovarian cancer in a first-in-human trial. These results were presented at ...

Contract research, development and manufacturing organisation (CRDMO) WuXi XDC Cayman has signed a memorandum of ...

Companies from these countries collectively account for 19 out of 28 assets worldwide. South Korea and China are leading in ...

AstraZeneca has tapped Korea's Alteogen to develop subcutaneous cancer drugs. Taiho Pharmaceutical is paying $400 million to ...